COVID-19 has placed the life sciences industry in Europe under extreme pressure, testing it like no other event. Lockdowns have shocked the system and exposed shortcomings. Every function has had to evaluate and adapt its
roles and responsibilities almost overnight. This is all made clear when in April, with Reuters Pharma, we surveyed over 1000 pharma professionals across pharma and biotech – from R&D to commercial – to find out how their functions were adapting and what they saw the future as holding.
This report explores its findings in detail, analyzing them with pharma leaders who are adapting to this new normal and leading their company’s strategies. It looks at the pandemic’s impacts and what this all means for the individual industry functions in the coming months and years.
Access this free 22+ page report and you will learn about:
Commercial’s ability to deliver virtual engagement
Gaps in the most commonly used CRMs as well as in data and analytics capabilities
The rise of Medical Affairs and the need to rethink its engagement with HCPs
Impact on R&D and the need to obtain RWE in new ways
Shifting payer priorities in light of pandemic
Learn what your peers believe will be the future of pharma.